ACME LaboratoriesDHA:ACMELAB +0.37%82 Operating Margin % is 15.02% as of Mar. 2026, which is 23% below its 10-year median of 19.42. GuruFocus rates DHA:ACMELAB with a GF Score™ of 82/100 and a GF Value™ of BDT124.74 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 955 Drug Manufacturers companies, ACME Laboratories ranks better than 74.66% on this metric.
ACME Laboratories Ltd operating margin has been in a 5-year decline. The average rate of decline per year is -2.7%.
The historical rank and industry rank for ACME Laboratories's Operating Margin % or its related term are showing as below:
DHA:ACMELAB'
s Operating Margin % Range Over the Past 10 Years
Min: 16.51 Med: 19.42 Max: 21.66
Current: 16.51
DHA:ACMELAB's Operating Margin % is ranked better than 74.66% of 955
companies
in the Drug Manufacturers industry
Industry Median: 7.45
vs DHA:ACMELAB: 16.51
ACME Laboratories's 5-Year Average Operating Margin % Growth Rate was -2.70% per year.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
ACME Laboratories Operating Margin % Related Terms
ACME Laboratories Operating Margin % Historical Data
* Premium members only.
The historical data trend for ACME Laboratories's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ACMELAB vs ZTS, UTHR, VTRS: Operating Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ACME Laboratories's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ACME Laboratories Operating Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ACME Laboratories's Operating Margin % distribution charts can be found below:
* The bar in red indicates where ACME Laboratories's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
ACME Laboratories's Operating Margin % for the fiscal year that ended in Jun. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACME Laboratories (DHA:ACMELAB) has a Operating Margin % of 15.02% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on ACME Laboratories and its competitors. This is 23% below median its historical median of 19.42. Over the past decade, ACME Laboratories' Operating Margin % has ranged from 16.51 to 21.66. According to the industry distribution chart, ACME Laboratories ranks #242 out of 955 companies in the Drug Manufacturers industry, placing it in the top 25.3%.
Is ACME Laboratories' Operating Margin % too high?
ACME Laboratories' current Operating Margin % of 15.02% is 23% below median its 10-year median of 19.42. Over the past 10 years, this metric has ranged from a low of 16.51 to a high of 21.66. The Drug Manufacturers industry median Operating Margin % is 7.45. ACME Laboratories' value of 15.02% is 101.6% above this industry median. Based on the distribution chart, ACME Laboratories ranks #242 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, ACME Laboratories has a GF Score™ of 82/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ACME Laboratories' Operating Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, ACME Laboratories ranks #242 out of 955 companies for Operating Margin %. This puts ACME Laboratories in the upper half of its industry. The industry median Operating Margin % is 7.45. ACME Laboratories' value of 15.02% is 101.6% above this benchmark. Historically, ACME Laboratories' own Operating Margin % has ranged from 16.51 to 21.66 over the past decade. While the company's 10-year median is 19.42 vs. the industry median of 7.45, ACME Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.45, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ACME Laboratories's current Operating Margin % of 15.02% is 101.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on ACME Laboratories and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ACME Laboratories's current Operating Margin % is 15.02%, which is 23% below median its own 10-year median of 19.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACME Laboratories stock overvalued right now?
Based on GuruFocus' analysis, ACME Laboratories (DHA:ACMELAB) is currently considered Possible Value Trap. The stock's GF Value™ is BDT124.74, compared to a current price of BDT81.30 — trading 34.8% below its estimated fair value. The current Operating Margin % is 15.02%, which is 23% below median its 10-year median of 19.42 and 101.6% above the Drug Manufacturers industry median of 7.45. ACME Laboratories' overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For ACME Laboratories (DHA:ACMELAB), the current Operating Margin % is 15.02% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACME Laboratories (DHA:ACMELAB) Overvalued in 2026?
Based on GuruFocus' analysis, ACME Laboratories stock appears to be undervalued.
The current stock price of BDT81.30 is trading 34.8% below its estimated GF Value™ of BDT124.74.
GuruFocus considers ACME Laboratories to be Possible Value Trap.
Key valuation signals for DHA:ACMELAB:
Operating Margin %: 15.02% (23% below median its 10-year median of 19.42)
GF Value™: BDT124.74 vs. price of BDT81.30 (34.8% below fair value)
Industry Position: 101.6% above the Drug Manufacturers median (#242 of 955)
No single metric tells the full story. See the DHA:ACMELAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ACME Laboratories Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products in Bangladesh. The Company is engaged in manufacturing, marketing, and distribution of generic pharmaceuticals formulation products which includes human drugs comprising dosages form like a tablet, capsule, dry syrup, cream, ointment, powder, injection, dry powder inhaler, metered dosage inhaler, suppository, eye and nasal drop, liquid, liquid in hard gelatine, Blow Fill Seal (BFS) products, sachet products; veterinary drugs comprising dosages form like bolus, liquid,injection, water-soluble powder, premix and herbal drugs comprising dosages form like liquid, capsule, tablet, cream. The products of the company are sold in domestic and international markets.
82GF Score
Get the complete analysis for DHA:ACMELAB
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ACMELAB has been successfully added to your 
